Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs

被引:16
作者
Ashton, JA [1 ]
Farese, JP [1 ]
Milner, RJ [1 ]
Lee-Ambrose, LM [1 ]
van Gilder, JM [1 ]
机构
[1] Univ Florida, Coll Vet Med, Dept Small Anim Clin Sci, Gainesville, FL 32610 USA
关键词
D O I
10.2460/ajvr.2005.66.885
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Objective-To determine the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells and non-neoplastic cells from dogs. Sample Population-3 osteosarcoma and 1 fibroblast cell lines derived from dogs. Procedure-Cell counts and cell viability assays were performed in cultures of osteosarcoma cells (POS, HMPOS, and COS31 cell lines) and fibroblasts after 24, 48, and 72 hours of incubation with pamidronate at concentrations of 0.001 to 1,000 mu M or with no drug (control treatment). Percentage viability was determined in cell samples for each concentration of pamidronate and each incubation time. A DNA fragmentation analysis was performed to assess bisphosphonate-induced apoptosis. Results-Osteosarcoma cell viability decreased significantly in a concentration- and time-dependent manner at pamidronate concentrations ranging from 100 to 1,000 mu M, most consistently after 48 and 72 hours' exposure. In treated osteosarcoma cells, the lowest percentage cell viability was 34% (detected after 72 hours' exposure to 1,000 mu M pamidronate). Conversely, 72 hours' exposure to 1,000 mu M pamidronate did not significantly reduce fibroblast viability (the lowest percentage viability was 76%). After 72 hours of exposure, pamidronate did not cause DNA fragmentation in POS or HMPOS cells. Conclusions and Clinical Relevance-Results indicate that pamidronate may have the potential to inhibit osteosarcoma growth in dogs, possibly through a nonapoptotic mechanism. The clinical relevance of these in vitro findings remains to be determined, but administration of pamidronate may potentially be indicated as an adjuvant treatment in chemotherapeutic protocols used in dogs.
引用
收藏
页码:885 / 891
页数:7
相关论文
共 43 条
[1]  
Barroga EF, 1999, J VET MED SCI, V61, P361
[2]   Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function [J].
Berenson, JR ;
Rosen, L ;
Vescio, R ;
Lau, HS ;
Woo, M ;
Sioufi, A ;
Kowalski, O ;
Knight, RD ;
Seaman, JJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (04) :285-290
[3]   Canine osteosarcoma - Amputation and chemotherapy [J].
Berg, J .
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 1996, 26 (01) :111-+
[4]   Dosing regimens and main adverse events of bisphosphonates [J].
Body, JJ .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :49-53
[5]  
BRODEY RS, 1969, CLIN ORTHOP RELAT R, P54
[6]   The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases [J].
Coleman, RE ;
Seaman, JJ .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :11-16
[7]  
DERNELL WS, 2001, SMALL ANIMAL CLIN ON, P378
[8]  
Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO
[9]  
2-W
[10]  
El-Abdaimi K, 2003, INT J ONCOL, V22, P883